NasdaqGS:DFTXPharmaceuticals
Definium Therapeutics (DFTX) Could Be 30% Overvalued After New GAD Study
What the new GAD study tells investors about Definium Therapeutics stock
Definium Therapeutics (DFTX) has put fresh clinical needs in the spotlight with a large healthcare claims study in CNS Spectrums showing many generalized anxiety disorder patients discontinuing or switching treatment far earlier than guidelines suggest.
For you as an investor, the findings matter because they quantify how often real world patients move away from current generalized anxiety disorder therapies or...